Stem Cell Transplant Trumps Fingolimod for RRMS Relapse Risk

Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.

Related Keywords

Australia , Czech Republic , Melbourne , Victoria , Prague , Praha , Hlavníesto , Sydney , New South Wales , Ottawa , Ontario , Canada , Tomas Kalincik , Kubala Havrdov , Eva Kubala Havrdov , Neuroimmunology Service , Research Gap , University Of Melbourne , Sclerosis Center At Charles University , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Medscape Medical News , Royal Melbourne Hospital , Multiple Sclerosis Center , Charles University , Multiple Sclerosis Ms , Us , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Disability , Disease Modifying Therapy , Mt , Hematology , Secondary Progressive Multiple Sclerosis , Pms , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Ematopo ,